NAD(P)H:quinone oxidoreductase 1 (NQO1) is a detoxification enzyme that protects cells against oxidative stress and toxic quinones. A polymorphism (C609T) in the gene produces in the heterozygous individuals (C/T) a reduction and in those homozygous for the variant allele (T/T) the abolishment of NQO1 protein activity. To assess whether NQO1 inactivating polymorphism (CT/TT) was a possible risk factor for infant acute lymphoblastic leukemia (iALL), we investigated the distribution of NQO1 genotype in 50 iALL patients, 32 with MLL gene rearrangements (MLL þ ) and 18 without (MLLÀ). As controls, 106 cases of pediatric ALL (pALL), and 147 healthy subjects were also studied. Compared to normal controls, the frequency of the low/null activity NQO1 genotypes was significantly higher in the iALL MLLÀ (72 vs 38%, P ¼ 0.006; odds ratio (OR) 4.22, 95% confidence interval (CI) 1.43-12.49), while no differences were observed in iALL MLL þ (44 vs 38%, P ¼ 0.553; OR 1.26, 95% CI 0.58-2.74). Similar results were observed when pALL were used as control. Our results indicate that only the iALL patients without MLL rearrangements had a significantly higher frequency of NQO1 genotypes associated with low/null activity enzyme, suggesting a possible role for NQO1 gene as an MLL-independent risk factor, in the leukemogenic process of this subtype of iALL.
Introduction
Infant leukemia (IL), defined as that occurring in the first 12 months of life, is a rare disease with poor prognosis and represents a biologically and clinically distinct disease from childhood leukemia. In fact, in this age group lymphoid and myeloid subtypes are equally distributed, 1 and rearrangements in the leukemic clone involve the MLL gene on chromosome band 11q23 in more than 70% of cases. [1] [2] [3] Epidemiological and molecular studies suggest that in IL critical molecular lesions occur in utero in early hematopoietic precursors or uncommitted cells. [4] [5] [6] [7] The etiology of IL is unknown and likely to involve a complex interaction between inherited genetic susceptibility, exposure to exogenous leukemogenic agents, and chance events. 8 The NAD(P)H:quinone oxidoreductase 1 (NQO1) gene, coding for the detoxification enzyme NQO1, is subject to a genetic polymorphism (C609T) (NCBI dbSNP:rs1800566), located in exon 6 , that causes a change in amino-acid sequence (Pro187Ser) and a low activity variant of the protein. 9 Previous studies showed that the NQO1 polymorphism was associated with risk of IL with MLL rearrangement. However, in these studies, IL was considered as a single group including both acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML), and NQO1 polymorphism seems to be more likely correlated to infant ALL (iALL). 10, 11 No information is available on the possible risk factors for IL without MLL rearrangement.
In order to provide additional data on the role of low NQO1 activity as possible risk factors for iALL, we investigated the distribution of the NQO1 genotype in an Italian population of 50 iALL patients, including subjects with and without MLL rearrangement, and compared it with that observed in normal controls and in other cases of pediatric ALL (pALL).
Materials and methods

Cases and controls
Italians ALL patients, either infant (age at diagnosis p12 months) or pediatric (age at diagnosis 412 months o15 years), enrolled in the Interfant-99 protocol or in the ALL-95 protocol of the Italian Association of Pediatric Hematology and Oncology (AIEOP) between 1995 and 2003 were eligible for this study. MLL gene rearrangements were evaluated at diagnosis by banded karyotyping, reverse transcription PCR or by fluorescence in situ hybridization. For this study, only cases with available biological material were selected. Healthy controls were children admitted to hospital for traumas, acute infectious episodes or minor surgical procedures. Written informed consent was obtained by the parents of patients and controls or from the patients and controls themselves whenever eligible, in accordance with the Helsinki Declaration of Principle. Ethics Committee of the G Gaslini Children's Hospital approved this study.
NQO1 genotype analysis
Genotyping of leukemic patients was performed on DNA extracted from bone marrow samples taken at diagnosis or, if not available, at any time during follow-up. DNA extracted from peripheral blood was used for healthy controls. Polymorphism of C609T NQO1 gene was analyzed by standard PCR/RFLP as described previously. 12 Based on genotype analysis, wild-type individuals (CC) were assigned to the high NQO1 activity category, while those heterozygous (CT) or homozygous (TT) for C609T polymorphism were assigned to the low/null activity category.
Statistical analysis
Comparison of frequency distribution between groups was made by means of the w 2 test; the Fischer's exact test was used in case of at least one expected frequency less than 5. All tests are twosided and P-value less than 0.05 have been considered as statistically significant. Crude odds ratios (OR) were also calculated and given with 95% confidence intervals (CI).
Results
Biological material was available for 50 of the 76 iALL patients diagnosed during the study period. The main demographic and clinical characteristics of children with or without DNA available did not differ; in particular, the prevalence of the different characteristics among the 26 children with no DNA available and the 50 included in the study were: male gender 46 vs 58%, P ¼ 0.34; age at diagnosis o6 months 38 vs 46%, P ¼ 0.63; white blood cells count 4100 000 46 vs 54%, P ¼ 0.63). With regard to the available information on MLL rearrangements, children with no DNA available were more likely to have not complete information since most of them were enrolled in the ALL-95 study in which MLL status was evaluated only by banded karyotyping and RT-PCR for t(4;11).
Distribution of C609T NQO1 polymorphism in iALL patients and leukemic or healthy controls is reported in Table 1 . There were 50 iALL patients (32 (64%) with the MLL gene rearrangement (MLL þ ) and 18 (36%) without (MLLÀ)), 106 pALL patients (12 (11%) were MLL þ and 94 (89%) were MLLÀ), and 147 healthy controls.
Genotype distribution was consistent with Hardy-Weinberg equilibrium in all populations. The genotype frequencies observed in healthy controls (62% CC/high activity, 38% CT þ TT/low/null activity) was comparable to that reported in Caucasians. 10, 13 No differences were found in the distribution of NQO1 genotypes comparing pALL with normal controls. The whole population of iALL patients showed a borderline significant shift toward the NQO1 CT/TT genotype (Table 1) with respect to normal controls (54 vs 38%, P ¼ 0.049, OR ¼ 1.91, 95% CI 1.00-3.65). However, if MLL þ (n ¼ 32) and MLLÀ (n ¼ 18) patients were considered separately, the frequency of the low/null NQO1 genotypes was drastically higher among MLLÀ subjects compared to normal controls (72 vs 38%, P ¼ 0.006, OR 4.22, 95% CI 1.43-12.49). Conversely, iALL MLL þ had a frequency of NQO1 polymorphism almost identical to that of healthy controls (44 vs 38%, P ¼ 0.553, OR 1.26, 95% CI 0.58-2.74). The differences became more significant if the genotype of iALL MLLÀ was compared with that of pALL overall (P ¼ 0.002) and with that of pALL MLLÀ (P ¼ 0.001) ( Table 1) .
Discussion
To our knowledge, this is the first study in which the analysis of NQO1 polymorphism has been performed in a group composed only of iALL cases including both MLL þ and MLLÀ patients. In our data, the frequency of the low/null activity polymorphism of NQO1 is significantly associated with the subset of iALL without MLL rearrangement, suggesting a possible role for this gene as a risk factor in the leukemogenesis of this subtype of iALL. Biological explanations of why the NQO1 polymorphism should be associated with this specific phenotype of iALL can only be speculative at present. The NQO1 enzymatic activity protects the cell against the oxidative stress and toxic quinone 14, 15 ; moreover, this protein was shown to interact with and stabilize the tumor suppressor protein p53. 16, 17 We can thus speculate that the reduced detoxifying power for toxic quinone and free radicals and/or the decreased stability of p53 resulting from the NQO1 inactivating polymorphism may influence the susceptibility to iALL with no MLL rearrangements. However, further investigation needs to verify this hypothesis and to understand the mechanism.
In our results, NQO1 inactivating polymorphism was not associated with iALL MLL þ , and this is in contrast to two different studies where MLL þ leukemias (ALL and AML) were found to be associated with the NQO1 low/null activity polymorphism. In particular, Wiemels et al 10 showed that infants up to the age of 18 months with MLL translocation in their leukemic cell had higher frequency of the low/null NQO1 genotype than normal controls. This was more pronounced when only ALL patients with t(4;11) translocation were considered. Similar observation was reported by Smith et al.
11
There may be different reasons to explain the discrepancy between our data and those of the other studies. A possible reason for differences with respect to Wiemels' study is the age limit. Indeed, we strictly referred to the most widely accepted definition of infant ALL, 1 thus evaluating only subjects diagnosed below the age of 12 months, whereas Wiemels MLL gene rearrangements were evaluated, at diagnosis, by karyotyping, reverse transcription-PCR using primers specific for AF4, ENL, AF9 fusion partner genes and/or fluorescence in situ hybridization. Only three MLL neg. patients were evaluated only by karyotyping and AF4 PCR.
included in his cohort patients up to the age of 18 months. It is of note that in a separate analysis we included in iALL MLLÀ group also children diagnosed between 12 and 18 months of age, and in this subgroup, the frequency of NQO1 CT þ TT genotypes was not statistically different to that of normal controls (data not shown). This indicates that conventional iALL (p12 months of age) represents a distinct biological subset for which the NQO1 polymorphism may be an important risk factor. This is also confirmed by the no difference of the distribution of the NQO1 genotype in pALL overall and pALL MLLÀ. A second reason may be the sample size. Indeed, due to the rarity of the disease, all these studies on this specific topic rely on a relatively small and roughly similar number of patients: 32 iALL MLL þ in our study, 30 and nine cases in the abovementioned reports. 10, 11 This suggests the need for international cooperative study, which may provide with larger samples size more reliable results.
A third possible explanation of the differences between our and others data is that they might reflect the differences in exposure to leukemogenic factor in different countries. It could be that our iALL patients might have undergone different exposure to leukemogenic factor compared to patients of other studies.
Moreover, in this respect also, the different parental carcinogen exposure may have played an important role in the IL, since an in utero pathogenesis of this disease has been suggested. This implies that testing the NQO1 genotype of the parents, and in particular of the mother, could be helpful in the understanding the influence of the NQO1 genotype in IL etiology.
On the basis of the high percentage of MLL rearrangements described in both IL and therapy-related leukemia, a common mechanism of leukemogenesis for these two types of ALL has been postulated. 18 Some studies on therapy-related leukemia 11, 19 have demonstrated that NQO1 low/null activity polymorphism is not associated with the presence of MLL rearrangements. This finding supports the hypothesis that low/ null activity NQO1 polymorphism and MLL rearrangements may be parts of two independent mechanisms of leukemogenesis.
In summary, our results indicate that low activity NQO1 polymorphism is associated with iALL without MLL rearrangements and not with iALL MLL þ as reported previously. This result supports the hypothesis that there are two independent mechanisms of leukemogenesis leading to iALL: one involving the tumor suppressor gene MLL and the other related to environmental exposure. 20 On the basis of this hypothesis, our data show that the low/null activity polymorphism of NQO1 gene could act as risk factor in the pathway of iALL not involving MLL gene rearrangements.
A larger study, including also the parental NQO1 genotype and the genetic analysis of other polymorphic genes involved in environmental exposure, could in understanding the leukemogenesis of iALL.
